· Ciledge Trio to address India’s growing hypertension burden
· Drug combines three well-established antihypertensive agents
· ‘To deliver efficacy, safety, and long-term cardiovascular protection’
Ahmedabad, April 10, 2026: Cadila Pharmaceuticals recently announced the launch of Ciledge Trio, a scientifically developed fixed-dose combination therapy designed to deliver sustained blood pressure (BP) control with improved tolerability and enhanced patient adherence. The launch responds to India’s rapidly escalating hypertension burden and the need for effective, guideline-aligned treatment options.
Ciledge Trio combines three well-established antihypertensive agents with complementary mechanisms of action: Cilnidipine (CCB), Telmisartan (ARB), and Metoprolol (a β1-selective blocker). This comes in line with the clinical evidence that supports combination therapy as a superior strategy for achieving sustained BP control and enhanced cardioprotective benefits, especially in hypertensive patients with co-existing cardiac conditions and myocardial infarction.
Compared to conventional CCBs, cilnidipine is associated with up to ten-fold lower incidence of pedal edema. When combined with telmisartan, it demonstrates effective and sustained BP control with a favorable safety profile, including benefits for patients with diabetes and chronic kidney disease. The addition of metoprolol further strengthens cardiovascular protection and heart rate control.
On the launch of Ciledge Trio, the company’s CMD, Dr. Rajiv I. Modi, said: “Cadila Pharmaceuticals reinforces its commitment to addressing unmet needs in hypertension management. This guideline-driven combination is designed to deliver efficacy, safety, and long-term cardiovascular protection — key elements for improving patient outcomes in real-world clinical practice.”
By integrating all three agents into a single-pill formulation, Ciledge Trio significantly reduces pill burden, thereby improving treatment adherence and long-term clinical outcomes. It aims to address the critical need for cardioprotection in a specific subset of hypertensive patients with underlying cardiac conditions, including angina, myocardial infarction, and heart failure.
Hypertension affects an estimated 220 million adults in India. While more than one in four individuals has elevated blood pressure, only a limited proportion receives timely diagnosis, appropriate treatment, or achieves optimal BP control.
Both global and Indian clinical guidelines recommend Calcium Channel Blockers (CCBs) and Angiotensin Receptor Blockers (ARBs) — preferably in combination — as first-line therapy for effective blood pressure management.
Cadila Pharmaceuticals continues to advance cardiovascular care through its world-first Tri-tab technology, an innovative triple-layered tablet platform that surpasses conventional bi-layered designs. This technology enables the rational combination of three active ingredients into a single, high-purity delivery system, ensuring enhanced stability, minimized drug–drug incompatibility, and consistent plasma drug levels.
The precise three-layer structure improves the absorption of all three components, offering a clear therapeutic advantage over traditional film-coated tablets.
Through the launch of Ciledge Trio, Cadila Pharmaceuticals continues to strengthen its cardiovascular portfolio and contribute meaningfully to improved hypertension control — an essential step in reducing India’s long-term cardiovascular disease burden.
Corporate Comm India (CCI Newswire)
